DEXTENZA is an advancement in steroid treatment1,2

  • Resorbable, so no need for removal1
    • Insert can be removed via saline irrigation or manual expression, if necessary1
  • Physicians rated DEXTENZA as easy to insert3,4*
  • Designed to deliver a tapered dose2
  • Contains fluorescein for visualization1
  • No additional components or assembly required1

*73.6% of physicians in Study 1, 76.4% in Study 2 and 79.6% in Study 3 rated DEXTENZA as easy to insert.

Over the course of 30 days post-op…

Built-in compliance with

To view the Phase 3 clinical program publications click here

Consider the preservative load

Preservatives (e.g., benzalkonium chloride) in some topical drops can cause changes in the ocular surface, which may lead to inflammation and damage to the tear film.6



DEXTENZA is dexamethasone delivered via hydrogel technology1,3


  • With moisture and swells to fit securely in the canaliculus


  • Dexamethasone for up to 30 days


  • Slowly through the course of treatment and clears via the nasolacrimal duct

References: 1. DEXTENZA [package insert). Bedford. MA: Ocular Therapeutlx, Inc: 2019. 2. Sawhney AS, Jarrett P, Bassett M, Blizzard C, inventors; Incept, LLC, assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 3. Walters T et al. J Clin Exp Ophthalmol. 2016;7(4): 1-11. 4. Tyson S. et al. J Cataract Refract Surg 2019; 45:204–212. 5. Data on file 00663. Ocular Therapeutix Inc. 6. Baudouin C et al. Prog Retin Eye Res. 2010;29(4):312-334.

Full Prescribing Information

DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.


DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

Warnings and Precautions
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Adverse Reactions
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

Please see Full Prescribing Information.